262 related articles for article (PubMed ID: 22684718)
1. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
4. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
5. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
[TBL] [Abstract][Full Text] [Related]
6. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
8. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.
Majeti BK; Lee JH; Simmons BH; Shojaei F
BMC Cancer; 2013 Apr; 13():213. PubMed ID: 23627488
[TBL] [Abstract][Full Text] [Related]
9. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
10. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S
PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499
[TBL] [Abstract][Full Text] [Related]
11. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Wainberg ZA; Alsina M; Soares HP; Braña I; Britten CD; Del Conte G; Ezeh P; Houk B; Kern KA; Leong S; Pathan N; Pierce KJ; Siu LL; Vermette J; Tabernero J
Target Oncol; 2017 Dec; 12(6):775-785. PubMed ID: 29067643
[TBL] [Abstract][Full Text] [Related]
12. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
13. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract][Full Text] [Related]
15. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
16. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
18. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
[TBL] [Abstract][Full Text] [Related]
19. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
20. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
[Next] [New Search]
